Abstract 2411: Non-invasive analysis for T790M mutations of EGFR using a selective amplification method

Abstract

Abstract Epidermal growth factor receptor (EGFR) T790M mutation is associated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance in non-small cell lung cancer (NSCLC). However, tissue availability limits the genotyping of EGFR T790M mutation in a clinical setting. The aims of this study are to develop a blood-based, non-invasive approach to detecting the EGFRT790M mutation in advanced NSCLC patients, using PointMan™ EGFR DNA Enrichment Kit, which is a novel method for selective amplification of genotype specific sequences. Methods: Blood samples were collected from NSCLC patients with activating EGFR mutations, who were resistant to EGFR-TKIs treatment. EGFR T790M mutations in plasma DNA were detected using the kit. The concentrations of plasma DNA were determined using quantitative real-time PCR. Results: 21 (87.5%) of the patients had EGFR T790M mutations in their plasma DNA as detected using the kit. In all 6 cases detected T790M mutations from tumor tissues, the T790M mutations ware detected also in plasma DNA. The concentrations of plasma DNA were higher in patients with T790M mutations than without the mutations. Conclusions: The PointMan™ is an easily and useful method for determining the plasma EGFR T790M mutation status. Citation Format: Shingo Nishikawa, Hideharu Kimura, Hayato Koba, Taro Yoneda, Takashi Sone, Chris Booth, Andrew Webb, Kazuo Kasahara. Non-invasive analysis for T790M mutations of EGFR using a selective amplification method. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2411. doi:10.1158/1538-7445.AM2015-2411